Concepedia

Author

Iryna Kryachok

National Cancer Institute

Also Known As

I Kryachok, I. A. Kryachok, I. Kryachok, I. Kryachоk, I.A. Kryachok, Iryna A. Kryachok, Iryna Kryachok, Lesya Yanitka, Olena Ibrahimova

50

Publications

540

Citations

11

H-Index

30

Concepts

All Affiliations

National Cancer InstituteKhmelnytskyi National UniversityMedical University of SilesiaNovartis (United States)Copernicus Memorial Hospital
IK

About

Iryna Kryachok is an author at National Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

275

2

Health Sciences

5

5

227

3

Immunology

4

4

227

4

Engineering

1

1

36

5

Cellular Therapies

1

1

34

Iryna Kryachok

×

11

Publications

462

Citations

11

H-Index

YearCitations

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko,

The Lancet Oncology

2018

132

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos,

Clinical Lymphoma Myeloma & Leukemia

2018

89

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

Tadeusz Robak, Krzysztof Warzocha, Govind Babu,

Leukemia & lymphoma/Leukemia and lymphoma

2016

57

Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident—With focus on immunoglobulin heavy chain gene analysis

N. Bilous, Ekaterina Davidova, Iryna Kryachok,

Leukemia Research

2007

36

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro,

Journal of Clinical Oncology

2020

34

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

Michael Wang, David Šálek, David Belada,

Journal of Clinical Oncology

2025

29

Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia

Anders Österborg, Miklós Udvardy, Andrey Zaritskey,

Leukemia & lymphoma/Leukemia and lymphoma

2016

25

Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

Meletios Α. Dimopoulos, Sosana Delimpasi, Maryana Simonova,

Journal of Clinical Oncology

2020

25

Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia

N. Bilous, Vladimir Saenko, Iryna Dyagil,

Leukemia Research

2017

12

Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell Non-Hodgkin’s Lymphoma

Kamil Kaplanov, Andrey Zaritskiy, Sergey Alexeev,

Blood

2014

12

Page 1